Multiply Labs collaborated with these life science industry leaders to demonstrate automated cell therapy manufacturing tasks, with an emphasis on cell expansion. The results of the proof-of-concept ...
Cell therapies are among the most promising, yet complex medicines being developed today. Multiply Labs' mission is to make these therapies more widely available by increasing manufacturing efficiency ...
Multiply Labs, a robotics firm, and Retro Biosciences, which is developing therapies to address age-related diseases, signed an agreement valued at up to $85 million to automate Retro’s approach to ...
On a quest to automate manual portions of the cell therapy production process, Multiply Labs is arming itself with two more pieces of industry-leading tech. The new kit comes on board a little less ...
Breakthrough partnership with Universal Robots transforms "artisanal" manufacturing, making personalized, life-saving cancer treatments affordable and widely available. Leveraging collaborative robots ...
Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is now leveraging NVIDIA's open ...
A novel approach to automating cell therapy manufacturing using industry-standard equipment can potentially reduce human errors, deliver higher quality product, and lower manufacturing costs by ...
Collaboration with AstraZeneca will focus on scaling cell therapy manufacturing using GMP-ready end-to-end robotic biomanufacturing technology SAN FRANCISCO--(BUSINESS WIRE)--#AstraZeneca--Multiply ...
Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is now leveraging NVIDIA’s open ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results